FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Respo	nses)																
1. Name and Address of Reporting Person * GOLDBERG DAVID C				2. Issuer Name and Ticker or Trading Symbol ENZO BIOCHEM INC [ENZ]							nbol		5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner				
(Last) (First) (Middle) C/O ENZO BIOCHEM INC, 527 MADISON AVE				3. Date of Earliest Transaction (Month/Day/Year) 01/29/2010							/Year)	X Officer (give title below) Other (specify below) VP, Corporate Development					
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)							/Day/Year)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person					
NEW YORK, N		(State)	(Zip)			Tr.			ъ :				D:	1 6 1		0 1	
		` ′		24 5	N	T	1						1		Beneficially	6.	7 N
(Instr. 3) Date			2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)			Cod (Ins			4. Securities Acquire (A) or Disposed of (Instr. 3, 4 and 5)			Beneficia Reported	nt of Securities ally Owned Following I Transaction(s)		Ownership Form:	Beneficial
						ode	V	Amoun	(A) or (D)	Price	(Instr. 3 a	7 and 4)		Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)		
Common Stock, par value \$0.01		01/29/2010				A		6,000	A	(1)	67,272 ⁽²⁾			D			
			Table II - I					quire	the fo	orm dis	plays a c	curre eficial	ntly valid lly Owned	OMB conf	spond unle trol numbe		
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security		Transaction eate Month/Day/Y	3A. Deemed Execution Date	te, if	4. Transaction Code ear) (Instr. 8)		5. Number a		ions, convertible securi 6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Owners Form of Derivati Security Direct (or Indire	Beneficia Ownershi (Instr. 4) D)	
					Code	V	(A)	(D)	Date Exerc	cisable	Expiration Date	Title	Amount or e Number of Shares				
Reporting	Ow	ners															

B 41 0 V	Relationships							
Reporting Owner Name / Address	Director	10% Owner	Officer					
GOLDBERG DAVID C C/O ENZO BIOCHEM INC 527 MADISON AVE NEW YORK, NY 10022			VP, Corporate Development					

Signatures

/s/ David C. Goldberg	02/02/2010
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The Reporting Person was granted 6,000 shares of restricted common stock, par value \$0.01 per share ("Common Stock"), of the Company on January 29, 2010 in connection with his service as an officer of the Company. The shares will vest in three equal annual installments, beginning on January 29, 2011.
- (2) Includes (i) 979 shares of Common Stock indirectly beneficially owned through the UGMA accounts of Mr. Goldberg's children, and (ii) 5,752 shares of Common Stock held in the Company's 401(k) plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.